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Abstract
Background—18p deletion syndrome is a rare disorder caused by partial or full monosomy of 
the short arm of chromosome 18. Clinical symptoms caused by 18p hemizygosity include 
cognitive impairment, mild facial dysmorphism, strabismus and ptosis. Amongst other genes, 
SMCHD1 is hemizygous in most patients with 18p deletions. Digenic inheritance of a SMCHD1 
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mutation and a moderately sized D4Z4 repeat on a facioscapulohumeral muscular dystrophy 
(FSHD) permissive genetic background of chromosome 4 can cause FSHD type 2 (FSHD2).
Objectives—Since 12% of Caucasian individuals harbor moderately sized D4Z4 repeats on a 
FSHD permissive background we tested if people with 18p deletions are at risk of developing 
FSHD.
Methods—To test our hypothesis we studied different cellular systems originating from 
individuals with 18p deletions not presenting FSHD2 phenotype for transcriptional and epigenetic 
characteristics of FSHD at D4Z4. Furthermore, individuals with an idiopathic muscle phenotype 
and an 18p deletion were subjected to neurological examination.
Results—Primary fibroblasts hemizygous for SMCHD1 have a D4Z4 chromatin structure 
comparable with FSHD2 concomitant with DUX4 expression after transdifferentiation into 
myocytes. Neurological examination of 18p deletion individuals from 2 independent families with 
a moderately sized D4Z4 repeat identified muscle features compatible with FSHD.
Conclusions—18p deletions leading to haploinsufficiency of SMCHD1, together with a 
moderately sized FSHD permissive D4Z4 allele, can associate with symptoms and molecular 
features of FSHD. We propose that 18p deletion patients should be characterized for their D4Z4 
repeat size and haplotype and monitored for clinical features of FSHD.
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Introduction
Facioscapulohumeral dystrophy (FSHD [OMIM:158900 and 158901]) is the third most 
common muscular dystrophy, most often inherited in an autosomal dominant fashion. It has 
an estimated prevalence of 1:8,300–22,000 depending on geographical location[1]. Clinical 
symptoms of FSHD include facial weakness, often noted by inability to whistle, shoulder 
girdle weakness recognized by difficulty in raising arms above shoulder level, and upper 
extremity muscle weakness. Muscle weakness can spread to the lower extremities with 
disease progression. In 20% of cases, disease progression results in wheelchair dependency. 
Beside muscle weakness, hearing loss and vascular retinopathy can be present; most often in 
patients with early onset FSHD. Presentation of initial clinical symptoms can vary from birth 
to middle age, but generally it starts in the second decade of life. Manifestation of the 
disease is highly variable between and within families with 12–30% of familial cases with a 
genetic diagnosis remaining asymptomatic. This high variability in disease presentation 
suggests a role for other genetic disease modifiers.
The molecular mechanism of FSHD has been largely elucidated and identified a key role for 
DUX4. DUX4 is a member of the double homeodomain protein family of transcription 
factors and is normally expressed in luminal cells of the testis[2, 3], in late-differentiating 
keratinocytes[4] and in thymus[3]. DUX4 was recently identified as key transcriptional 
regulator in early stage embryos where it initiates zygotic genome activation[5–7]. 
Inappropriate expression in skeletal muscle leads to an early embryonic transcriptional 
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program, eventually resulting in muscle degeneration and the diagnosis of FSHD[8, 9]. A 
copy of the DUX4 gene is located within each unit of the D4Z4 macrosatellite repeat at 
4q35. This D4Z4 repeat is polymorphic forming arrays of 8–100 units which are in a 
repressed chromatin state in skeletal muscle of healthy individuals. When the D4Z4 repeat is 
generally between 1–10 units the chromatin can become relaxed. When this occurs on a 
genetic background of chromosome 4 that contains a non-canonical DUX4 polyadenylation 
signal (PAS) distal to the D4Z4 repeat a stable DUX4 transcript is produced in muscle 
cells[10]. Population studies have shown that the polymorphic DUX4 PAS is present on 
approximately half of chromosomes 4 in the Caucasian and Asian population[11].
Patients diagnosed with FSHD are currently classified into 2 groups based on cis (FSHD1) 
or trans (FSHD2) genetic variants leading to D4Z4 chromatin relaxation. More than 95% of 
FSHD patients have a cis mechanism of disease; contraction of the D4Z4 repeat to a size of 
1–10 units on a FSHD permissive (i.e. DUX4 PAS containing) chromosomal background, 
usually 4q35 (4qA; FSHD1). Less than 5% of patients have disease from a trans mechanism; 
a moderately sized (8–20U in most cases)[12] D4Z4 repeat on a FSHD permissive 
chromosome 4qA, combined with a heterozygous mutation in genes regulating the 
chromatin structure at D4Z4 in somatic cells (FSHD2). At least 85% of FSHD2 patients 
have a mutation in the Structural Maintenance of Chromosomes Flexible Hinge Domain 
Containing 1 (SMCHD1)[2] gene located on the short arm of chromosome 18 while in two 
FSHD families mutations in the DNA Methyltransferase 3 Beta (DNMT3B) gene[13] on 
chromosome 20 have been identified. While in FSHD1 chromatin relaxation is restricted to 
the shortened D4Z4 repeat, in FSHD2 the epigenetic changes are present on all genomic 
regions regulated by SMCHD1 or DNMT3B, including both D4Z4 repeats at 4q35 and the 
highly homologous D4Z4 like repeats at 10q26.
The first epigenetic finding in FSHD was a significant reduction of D4Z4 DNA methylation 
in patients[14]. Changes in histone modifications were also detected in FSHD samples 
compared to controls. Somatic cells of controls show the presence of the repressive 
H3K9me3 and H3K27me3 histone modifications at D4Z4, but unusual for heterochromatin, 
H3K4me2, a permissive histone mark, is also present at low levels[15]. Patient primary 
myoblasts, myotubes and fibroblasts[15, 16] have reduced H3K9me3 levels, and a 
significant increase of H3K27me3 was reported in FSHD2, but not FSHD1 [4]. Furthermore, 
SMCHD1 mutation carriers have significantly lower amounts of SMCHD1 at D4Z4 than 
controls.
The mutations in SMCHD1 that result in FSHD2 are distributed over the entire locus. Since 
about 30% of FSHD2 patients carry a nonsense mutation in SMCHD1, these likely lead to 
degradation of mutant mRNA by nonsense mediated decay (NMD), resulting in the observed 
decreased SMCHD1 transcript levels[14]. We therefore hypothesized that conditions leading 
to SMCHD1 haploinsufficiency are a risk factor for FSHD. We previously described 2 
families with a monoallelic 1,2Mb interstitial deletion of 18p, including SMCHD1 and 4 
neighboring genes with a classical FSHD phenotype without additional clinical 
symptoms[12]. Deletions of 18p occur in 1:50,000 individuals and lead to development of 
18p deletion (18p-) syndrome. The main clinical features of 18p- syndrome include mental 
impairment characterized by borderline to low normal IQ, motor and speech delay, global 
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hypotonia, abnormal brain MRI findings, autoimmune disorders and cardiac abnormalities. 
Hypotonia may cause weakness in the mouth muscles, but there is generally no muscle 
weakness, unlike the weakness observed in FSHD. Systematic collection and 
characterization of patients showed that deletions of 18p can vary in size: approximately 
50% of patients have a breakpoint in the centromeric region thereby creating hemizygosity 
of the entire short arm of one of their chromosomes 18, encompassing 66 genes. The 
remainder of the patients have terminal deletions with breakpoints all along the chromosome 
arm, with microdeletions rarely described. Recent studies focus on identifying correlations 
between phenotype and hemizygosity for individual genes as a result of an 18p deletion[17]. 
Since a heterozygous SMCHD1 deletion together with 4 neighboring genes is associated 
with FSHD, but not with an 18p- syndrome phenotype[12] we aimed to explore if 18p- 
patients, missing one copy of SMCHD1 and several to dozens of other genes have clinical or 
cellular signs of FSHD. Here we describe 2 families with a complex clinical picture with 
features of 18p- syndrome and FSHD and combine this with molecular studies of the D4Z4 
repeat in cell lines of individuals with FSHD or 18p- syndrome.
Materials and Methods
Clinical studies
Samples were obtained with informed consent and the study was approved by the 
appropriate Institutional Review Boards.
Cell lines, culturing conditions of human primary fibroblast, myoblast and LCLs
Human primary myoblast cell lines were isolated from muscle biopsy of patients 
Rf1731.103 and Rf1731.201 at University Nice, France. Primary myoblasts were cultured 
and fused for 72 hours as described previously[4]. Human primary fibroblast cell lines were 
received from the University of Rochester bio repository (http://www.urmc.rochester.edu/
fields-center/), from the University of Texas Health Science Center at San Antonio, or were 
derived from a lower extremity skin biopsy at the Leiden University Medical Center. 
Primary fibroblasts were cultured according to a published protocol[16]. LCL cell lines were 
obtained from the University of Texas Health Science Center at San Antonio and from the 
Leiden University Medical Center and were cultured according to published protocol[18]. 
The list of cell lines included in the study, origin, D4Z4 repeat size, genotype and 
experimental use are listed in Supplemental table 1.
Transdifferentiation of human primary fibroblasts into myogenic cell cultures
Transdifferentiation of fibroblasts was achieved by ectopic expression of MyoD, or GFP as 
control, as described previously[13]. Every transdifferentiation experiment was performed 
twice independently and figures show the average of these 2 experiments.
RNA isolation, cDNA synthesis and qRT-PCR
Samples originating from different cell cultures used in the study were harvested in QIAzol 
lysis reagent (#79306 Qiagen N.V., Venlo, The Netherlands) for RNA isolation. RNA 
isolation, cDNA synthesis and qRT-PCR reactions were performed as described 
previously[4].
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Histone ChIP-qPCR experiments were carried out as described before[16] using 3μg 
chromatin per reaction and antibodies against H3 (ab1791, 2μl/reaction, Abcam, Cambridge, 
UK), H3K9me3 (39161, 5 μl/reaction, Active Motif, Carlsbad, USA), H3K27me3 (17-622, 5 
μl/reaction, Merck-Millipore, Amsterdam Zuid-Oost, The Netherlands), H3K4me2 (39141, 
5 μl/reaction Active Motif, Carlsbad, USA) and total IgG (5 μl/reaction, Merck-Millipore, 
Amsterdam Zuid-Oost, The Netherlands). SMCHD1 ChIPs were performed as described 
before[2] using 60 μg chromatin per reaction and antibody against SMCHD1 (ab31865, 5 
μg/rxn, Abcam, Cambridge, UK). qPCR was performed as described previously[4]. Every 
ChIP-qPCR experiment was performed 2 independent times and figures show the average 
values.
Western blots
Patient primary myoblasts and primary fibroblasts were lysed in Radio-Immunoprecipitation 
Assay (RIPA) Buffer (0.1% SDS, 1% NP40, 0.5% sodiumdeoxycholine, 150mM NaCl, 
5mM EDTA and 1× Complete protease inhibitor cocktail (Roche, Basel, Switzerland) in 20 
mM Tris pH 7.4. The lysate was sonicated using a Bioruptor Pico (Diagenode, Liege, 
Belgium) and centrifuged for 10 minutes at 13.500 RPM to pellet the cell debris. Protein 
concentration was determined using Pierce BCA protein assay kit (Thermo Fisher Scientific, 
Waltham, MA) and equal protein amounts were boiled in 1× Laemmli Sample Buffer (2% 
SDS, 10% glycerol, 2% β-mercaptoethanol and 0.01% bromophenol blue in 60 mM Tris 
pH6.8). Samples were loaded on Criterion TGX 4–20% gels (Bio-Rad, Hercules, CA) and 
transferred to an Immobilon-FL PVDF membrane (EMD Millipore, Billeria, MA). The 
membrane was subsequently blocked in 4% skim milk in PBS and probed for SMCHD1 
(ab176731, Abcam, Cambridge, UK), α-Tubulin (T6199, Sigma Aldrich, St. Louis, MO) or 
HSP90 (#4874, Cell Signaling Technology, Danvers, MA) in Immunobooster (Takara Bio 
Inc. Kusatsu, Japan). Membranes were incubated with donkey-α-rabbit IRDye-800 and 
donkey-α-goat IRDye-680 (Li-cor, Lincoln, NE) followed by visualization of 
immunocomplexes using an Odyssey Infrared Imaging System (Li-cor, Lincoln, NE). 
Protein quantification was performed using the accompanying software package.
Immunofluorescence detection of DUX4 and high-throughput microscopy analysis
Cells were fixed with 2% paraformaldehyde and permeabilized with 1% Triton in PBS. 
Primary antibody against DUX4 (Abcam ab124699) was diluted 1:2000 in PBS and primary 
antibody detecting MYH1E (MF20, Hybridoma Bank, Iowa University) was diluted 1:1000 
in PBS. Secondary antibodies Alexa 488 conjugated anti-rabbit (A21206, Thermo Fisher 
Scientific, Waltham, MA, USA) and Alexa 594 conjugated anti-mouse (A21203, Thermo 
Fisher Scientific, Waltham, MA, USA) were diluted 1:500 in PBS. Visualization of nuclei 
was achieved by incubation with DAPI (4′,6-Diamidine-2′-phenylindole dihydrochloride, 
Sigma-Aldrich, 268298) diluted 1:1000 in PBS. Transdifferentiated fibroblasts (Figure 5C) 
were imaged with Thermo Cellomics Arrayscan@ VTI HCS Reader and 500 images per cell 
line were taken at 20× magnification. Number of nuclei in myotubes were determined by 
analyzing images with a custom made colocalization program in HCS studio software. 
Number of DUX4 positive nuclei was determined by manual screening of all images. 
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Primary myoblast cultures shown in Figure 2E were imaged with Nicon Eclipse Ti 
microscope equipped with A1 confocal detector at 20× magnification.
Statistical analysis
All statistical analysis was done using GraphPad Prism 6 software and the statistical method 
applied in different experiments is described in the results section and figure legends. 
Scatterplots and bar diagrams show the mean and standard deviation of the mean.
Results
18p- individuals can show clinical signs of FSHD
Clinical diagnosis of individuals with contiguous gene syndromes can be challenging 
because of their complex phenotype and are therefore more often diagnosed through genetic 
analysis. Identification of a FSHD phenotype in individuals with SMCHD1 monosomy as a 
result of an 18p deletion combined with a FSHD permissive moderately sized D4Z4 repeat 
is challenging because of the wide spectrum of symptoms associated with 18p- syndrome 
and the well documented inter- and intra-familial clinical variability in FSHD. From our 
patient cohort we identified 3 individuals from 2 families having an interstitial deletion of 
18p and clinical signs of FSHD. These individuals were subjected to detailed clinical 
examination. Array CGH was performed to define the 18p deletion. The FSHD diagnosis 
was confirmed based on the identification of a FSHD permissive 4qA haplotype, D4Z4 
repeat sizing and by DNA methylation analysis[14].
Family 1
The index case (Rf1731.102, 18p-9, Figure 1A, B) was first examined at age 26 when she 
started having difficulty in lifting her arms overhead. Physical examination showed classical 
features of FSHD such as asymmetrical facial and shoulder girdle weakness with scapular 
winging, mild paravertebral and abdominal muscle involvement, and asymmetrical muscle 
wasting of the anterior compartment of the leg. Total CPK blood levels were increased up to 
245 UI/L (normal range < 200 UI/L). Cardiac screening did not show major abnormalities. 
At age 50 she was wheelchair dependent with a clinical severity score (CSS)[19] of 8. 
Besides FSHD-like symptoms mild intellectual disability (IQ 65), short statue, ocular ptosis 
and strabismus were also observed. She also had micrognathia, low-set ears, hyperlordosis 
and bilateral pes cavus. The MRI of the brain showed white matter abnormalities and the 
muscle biopsy examination revealed non-specific dystrophic changes consistent with FSHD. 
D4Z4 repeat sizing identified one D4Z4 repeat of 12 units and one of 13 units, each on a 
FSHD permissive 4qA chromosome. Based on D4Z4 DNA methylation testing in genomic 
DNA from peripheral blood mononuclear cells (PBMCs) a delta1 value of -24% was 
established which is in the range of FSHD2 methylation values (<-21%) (Figure 1A). Array 
Comparative Genomic Hybridization (aCGH) analysis showed a 1.2 Mb deletion (arr[hg19] 
18p11.32p11.31(1,852,498–3,039,186)x1) affecting 5 protein coding genes including 
SMCHD1 (METTL4, NDC80, SMCHD1, EMILIN2, LPIN2). Furthermore, an interstitial 
duplication of 151 kb proximal to the deletion was detected (arr[hg19] 18p11.31(3,553,032–
3,703,842)×3) affecting exons 5, 6 and 7 of DLGAP1 and the uncharacterized antisense 
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transcripts DLGAP1-AS1 and DLGAP1-AS2 (BC094703) (Supplemental figure 1A). This 
figure also shows the 18p deletion in the previously described FSHD2 families[12].
The daughter of the index case (Rf1731.201, 18p-10, Figure 1A, B) was examined first at 
the age of 16 at which age she did not present any sign of symptoms. She started to display 
signs at the age of 24 with mild scapular and abdominal weakness, as well as asymmetrical 
ocular ptosis and strabismus. No cardiac anomalies were detected by transthoracic 
echocardiography and by a 24-hour Holter monitoring, as well as by cardiorespiratory 
physical examination. Pulmonary function test indicated a moderate restrictive pattern. 
Physical examination also showed short stature, round fixed face, transverse smile, 
micrognathia, low-set ears with detached pinnae and short fingers. Intellectual disability was 
not evident but not formally measured. Muscle biopsy performed in vastus lateralis muscle 
showed mild non-specific dystrophic changes.
D4Z4 repeat sizing showed that she inherited the FSHD permissive D4Z4 repeat of 12 units 
from her mother and a 23 units long D4Z4 repeat on a 4qB non-permissive allele from her 
father. DNA methylation analysis was performed in PBMCs revealing a delta1 methylation 
value of −30% which is in the FSHD2 range (Figure 1A). Array CGH analysis showed the 
presence of the same heterozygous 1.2 Mb deletion and 151 Kb duplication on 18p as 
observed in the mother.
Based on the muscle phenotype, the presence of 12 and 13 units long D4Z4 repeats on 
permissive haplotypes, SMCHD1 haploinsufficiency and D4Z4 hypomethylation, the 
diagnosis of FSHD2 was confirmed in both individuals.
Family 2
The proband (Rf1877.201, Figure 1C, D) presented at age 13 with elevated levels of total 
blood CPK (up to 2727 UI/L), which dropped to slightly elevated levels at age 17 (262UI/L). 
Cardiac screening did not show abnormalities. He progressively developed difficulty in 
lifting his arms overhead, orbicularis oris and oculi muscle weakness with fixed face and 
transverse smile, moderate scapular and humeral muscle weakness with scapular winging 
and mild quadriceps femoris muscle weakness. Physical examination also revealed a short-
broad neck, high-arched palate, hyperlordosis, as well as moderate calf hypertrophy and 
muscle wasting in pectoralis major and quadriceps femoris muscles. Muscle biopsy 
examination did not show any pathological changes, which is not uncommon for FSHD 
given the often focal nature of the disease. D4Z4 repeat sizing detected a repeat of 12 units 
on a FSHD permissive 4qA allele, which excluded FSHD1. DNA methylation analysis 
resulted in a delta 1 value of -23% which is in the FSHD2 range. Based on the presence of 
moderately sized permissive D4Z4 repeat at a permissive 4qA allele and low D4Z4 DNA 
methylation FSHD2 was diagnosed in this individual. Array CGH analysis showed the 
presence of a 3.7 Mb terminal deletion on 18p (arr[hg19] 18p11.32p11.31(136,226–
3,709,404)×1) that besides SMCHD1 includes 19 additional protein coding genes. This 18p 
deletion was not detected in other members of the family.
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18p hemizygosity leads to reduced SMCHD1 RNA and protein levels associated with DUX4 
expression in muscle cells
To determine whether SMCHD1 hemizygosity leads to decreased SMCHD1 expression, 
RNA and protein from proliferating and differentiated muscle cell cultures was analyzed by 
qRT-PCR and western blotting, respectively. We assayed myotube cultures from individuals 
with 18p deletions who had been clinically diagnosed with FSHD2 but not with the clinical 
features of 18p- syndrome[12] and cultures from the 2 individuals in family Rf1731 
presenting with features of 18p- syndrome and FSHD. SMCHD1 transcript levels were 
significantly reduced in 18p-myoblast (n=5, unpaired t-test test p<0.01) and myotube (n=5, 
unpaired t-test test p<0.05) cultures compared to control myoblast (n=7) and myotube (n=7) 
cultures (Figure 2A). Semiquantitative western blot analysis using HSP90 as loading control 
showed that control myotube cultures express significantly higher levels (unpaired t test 
p<0.05) of SMCHD1 than SMCHD1 hemizygous samples (Figure 2B and C).
Next, we asked if the lower SMCHD1 levels result in transcriptional derepression of DUX4 
in the 18p deletion samples, as was shown in FSHD2 patient samples with SMCHD1 
mutations[2, 4]. We detected DUX4 and DUX4 target gene expression by qRT-PCR in 
myoblast and myotube cultures of Rf1731.102 and Rf1731.201 (Figure 2D, Supplemental 
figure 2B, C) while myogenic differentiation was monitored by MYOG expression levels 
(Supplemental figure 2A). Although DUX4 target gene expression indicates that 18p 
deletion myotube cultures express DUX4 protein, we aimed to detect DUX4 by 
immunofluorescence microscopy to explore if individual 18p deletion myotubes exhibit the 
same pattern of sporadic nuclei expressing DUX4 as is found in FSHD. Sporadic expression 
of DUX4 was found in both myotube cultures, albeit with different frequencies (Figure 2E).
To test if SMCHD1 hemizygosity results in reduced SMCHD1 levels in tissues other than 
muscle, we studied immortalized lymphoblast cell lines (LCLs) and fibroblasts from control, 
FSHD and individuals with 18p deletions who had not been diagnosed with FSHD2. 
SMCHD1 mRNA quantification by qRT-PCR in LCLs and primary fibroblasts with 1 copy 
or 2 copies of SMCHD1 (samples are listed in Supplemental table 1) showed that SMCHD1 
mRNA levels were significantly reduced (fibroblast unpaired t-test test p<0.01, LCLs 
unpaired t-test p<0.0001) in samples with 1 copy of SMCHD1 (Figure 3A, B). 
Semiquantitative western blot analysis of primary fibroblasts with one (n=8) or 2 copies 
(n=8) of SMCHD1 using tubulin as control showed a significant (unpaired t-test p<0.05) 
reduction in SMCHD1 protein levels in 18p deletion primary fibroblasts compared to 
controls (Figure 3C, D).
In summary, our results show that all 18p deletion samples have lower SMCHD1 RNA and 
protein content and that this situation is associated with DUX4 and DUX4 target expression 
in individuals with a relatively short D4Z4 repeat on a FSHD permissive chromosomal 
background, similar to FSHD.
D4Z4 chromatin in 18p- cell lines shows similar epigenetic characteristics as in FSHD2
Because of the reduced SMCHD1 levels, we asked if primary fibroblasts from individuals 
with 18p deletions who have not been diagnosed with FSHD2 also show D4Z4 chromatin 
Balog et al. Page 8













changes characteristic of FSHD2. As previously reported in PBMCs from 18p- syndrome 
individuals[12], we found significantly reduced D4Z4 DNA methylation levels (n=6 control 
samples and n=8 18p-samples, unpaired t-test p<0.01)) in fibroblasts from these individuals, 
comparable to what was found in FSHD2 patients (Figure 4A). In concordance with 
previous observations in FSHD2 individuals, ChIP-qPCR on chromatin isolated from human 
primary fibroblasts (n=8 one copy and n=8 two copies of SMCHD1) showed a significant 
(unpaired t-test p<0.05) decrease in SMCHD1 binding at D4Z4 in samples hemizygous for 
SMCHD1 compared to controls (Figure 4B).
Next we investigated if changes in histone modifications are present on D4Z4 in 18p- 
fibroblasts. Consistent with our previous report[4], ChIP-qPCR with antibodies against 
H3K27me3, H3K9me3 and H3K4me2 showed that H3K9me3 levels at D4Z4 do not differ 
(Supplemental figure 3) but that H3K27me3 levels, like in FSHD2, were significantly 
increased in 18p- samples (unpaired t-test p<0.05, Figure 4C). Furthermore, we detected 
significantly increased H3K4me2 levels (unpaired t-test p<0.05) at D4Z4 in fibroblasts 
hemizygous for SMCHD1 compared to controls, as reported in FSHD[16] (Figure 4D).
Altogether our study revealed striking similarities between the D4Z4 chromatin structure in 
FSHD2 and 18p- fibroblasts suggesting that indeed 18p- patients are at risk of expressing 
DUX4 in somatic tissue.
DUX4 is expressed in different in vitro systems originating from patients with 18p 
deletions
Besides in myogenic cells DUX4 expression has also been reported in FSHD LCLs[18] and 
in FSHD primary fibroblasts after transdifferentiation in myocytes[13]. To test for DUX4 
expression in individuals with 18p- and a permissive 4q35 allele, we transdifferentiated 
control (n=3) and 18p- (n=6) primary fibroblasts by lentiviral MyoD transduction. 
Transdifferentiation was monitored by the presence of the late myogenic marker MYH3 
(Figure 5A). DUX4 (Figure 5B) and DUX4 targets KHDCL1 and ZSCAN4[20] 
(Supplemental figure 4A, B) were detected in 18p-samples at similar levels as FSHD1 and 
FSHD2 fibroblasts after efficient transdifferentiation, while fibroblasts transduced with GFP 
as control expressed no or negligible levels of DUX4 and its targets.[13]
Because of the variegated nuclear expression of DUX4 in FSHD, we employed high content 
immunofluorescence microscopy allowing us to screen at least 10,000 nuclei per sample for 
the presence of DUX4. High content imaging of transdifferentiated control (n=3) and 18p- 
(n=7) fibroblasts allowed, despite the variability in transdifferentiation, for the detection of 
DUX4 only in 18p- cell cultures but not controls. We detected DUX4 positive nuclei in 5 out 
of 7 18p- cell cultures with the number of DUX4 positive nuclei varying between the cell 
lines (Figure 5C, Supplemental table 2).
Finally, we analyzed a cohort of 18p- (n=17), control (n=13) and FSHD1 (n=10) LCL cell 
lines (the same cohort as included in the SMCHD1 expression analysis) for DUX4 and 
DUX4 target gene expression. All samples included in the study were sized for D4Z4 repeat 
at 4q35 and all cell lines had their shortest D4Z4 repeat on a FSHD permissive DUX4 PAS 
containing chromosome. Since D4Z4 array length also correlates with DUX4 expression[1] 
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control LCLs were selected with similar D4Z4 repeat sizes at a permissive 4q35 with sizes 
ranging between 13 and 35 units (Supplemental table 1). We detected significantly higher 
DUX4 levels (FSHD1; one way ANOVA p<0.0001, 18p-; one-way ANOVA p<0.05) in 
FSHD1 and 18p- LCLs compared to controls (Figure 6A). The relative expression of three 
DUX4 target genes was also determined. MBD3L2 and TRIM43 expression was 
significantly increased in FSHD1 (Figure 6B, C, one way ANOVA, TRIM43 p<0.05, 
MBD3L2 p<0.001) and 18p- LCLs (one way ANOVA, TRIM43 p<0.001, MBD3L2 
p<0.001). ZSCAN4 expression levels did not significantly differ between controls and 
FSHD1 (Figure 6D) while it was significantly increased in 18p- samples (one way ANOVA, 
p<0.01).
In general, DUX4 and TRIM43 expression levels were similar between myotubes, LCLs and 
transdifferentiated fibroblasts of FSHD1 and 18p- individuals, although quite some 
variability was observed in transdifferentiated fibroblasts possibly as a consequence of the 
transduction efficiency (Supplemental figure 5). Highest DUX4 expression was detected in 
18p- LCL samples with the shortest D4Z4 repeat of 13 units (n=2, Supplemental figure 6) 
and 15 units (n=1). Interestingly DUX4 expression of 18p- samples with repeats of 25 D4Z4 
units was still above control levels. Together these results show that different cell systems 
originating from 18p-individuals can express DUX4 and DUX4 targets similar to FSHD and 
that the level of DUX4 expression is dependent on the size of the permissive D4Z4 repeat.
Discussion
Based on the occurrence of a moderately sized D4Z4 repeat on a FSHD permissive 
chromosomal background we estimated that about 12% of 18p- patients are at risk of 
developing FSHD in the European population[12]. Our current study shows that individuals 
with 18p deletions, being hemizygous for SMCHD1 and few to 65 additional genes on 18p, 
can develop symptoms compatible with FSHD and display a molecular signature of FSHD 
in different cellular systems. We show in all in vitro models tested that SMCHD1 
hemizygosity is associated with reduced SMCHD1 transcript and protein levels. At D4Z4, 
reduced SMCHD1 binding is associated with increased H3K27me3, H3K4me2 levels, and 
reduced DNA methylation levels, the latter corroborating our previous report of reduced 
D4Z4 DNA methylation levels in blood samples of people with 18 deletions[12]. The 
observed D4Z4 DNA hypomethylation, the significant increase in the transcriptionally 
permissive H3K4me2 histone modification and the increase in the repressive H3K27me3 
modification, resembles the epigenetic landscape of D4Z4 in FSHD2, and suggests that the 
D4Z4 chromatin state is permissive for DUX4 transcription in somatic tissue of individuals 
with 18p-.
Indeed, we detected DUX4 expression in primary fibroblasts of individuals with variably 
sized deletions on chromosome 18p including SMCHD1 after transdifferentiation into 
myocytes. We extended our study to LCLs because a recent publication showed DUX4 and 
DUX4 target gene expression in FSHD LCLs[18]. We could confirm the presence of DUX4 
and some DUX4 targets at equal levels in FSHD LCLs, the absence in control LCLs, and 
extended this observation by showing DUX4 and DUX4 target gene expression in LCLs of 
individuals with 18p-. Several studies have reported that the epigenetic structure of the 
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disease locus is similar in different tissues[4, 21, 22], and DUX4 expression has also been 
reported in non-myogenic tissues of non-affected individuals[3, 23, 24]. However, given the 
significant transformation that LCLs have undergone, the clinical relevance of DUX4 
expression in these cell lines is likely very limited.
Besides SMCHD1 activity, DUX4 expression is also dependent on the size of the D4Z4 
repeat: longer D4Z4 repeats are less likely to express DUX4 than shorter repeats. We 
therefore measured D4Z4 repeat sizes in all samples included in the study and in agreement 
with earlier observations higher DUX4 expression was detected in 18p- samples with shorter 
D4Z4 repeats on a permissive chromosome 4qA than in those with longer repeats. 
Importantly, those 18p-samples with repeats of 13–15 units had the highest expression but 
18p- samples harboring repeats of 15–25 D4Z4 units still expressed DUX4 above controls. 
Our initial estimation, predicting that about 12% individuals with 18p- might be at risk of 
developing FSHD based on SMCHD1 monosomy and a D4Z4 repeat ≤16 units on a 
permissive chromosome 4 may, in light of these findings, be an underestimation. When 
using a threshold of ≤25 units based on the observation of DUX4 expression in LCLs, 
almost one-third of individuals with 18p- might be at risk of developing FSHD. However, as 
we rarely find patients with >16 units in the FSHD2 patient population[14] it might suggest 
that DUX4 expression levels in tissue culture may not necessarily reflect the levels in vivo 
and be predictive for pathogenicity.
The clinical diagnosis of FSHD in individuals with 18p- may be challenging because of the 
presence of additional signs and symptoms related to 18p- syndrome. In particular, the 
presence of extra-ocular muscle involvement and dysmorphic features are confounding and 
may suggest other diagnosis. In family Rf1731 we identified a deletion on 18p that is almost 
identical to the deletions reported earlier in two classical FSHD2 families, affecting the same 
five genes on 18p. While clinically different, the main genetic difference between Rf1731 
and the earlier reported FSHD2 families is the duplication of 150kb adjacent sequence in 
Rf1731 affecting exons 5, 6 and 7 of DLGAP1 and two antisense transcripts DLGAP1-AS1 
and DLGAP1-AS2. The database of Genomic Variants lists 3 large duplications 
(nsv1059696[25], dgv184n21[26] and esv2758710[27], Supplemental figure 1B) that 
partially overlap with this region. These variants were found in studies performed in the 
control population and predicts that this duplication represents a variant without clinical 
significance. Although DLGAP1 is part of the postsynaptic scaffold and has been suggested 
to associate with obsessive-compulsive disorder[28], its role in the neurological disease 
aspects of this family remains enigmatic. Considering the clinical variability in FSHD and 
18p- syndrome, each representing conditions in which the clinical variability may vary from 
non- or minimally affected to severe in individuals carrying the same genetic defect, it is 
perhaps not surprising that almost identical deletions at 18p may result in a pure FSHD 
phenotype or a combination of clinical features of FSHD and 18p-syndrome. Alternatively, 
since SNP array analysis cannot determine the genomic location of the 150kb duplication, it 
is possible that this duplication has integrated somewhere else in the genome and thereby 
disrupting or altering the expression of unknown loci.
In summary, our study highlights the complex and variable clinical outcome of SMCHD1 
haploinsufficiency and supports the conclusion that people with 18pdeletions should 
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routinely be genetically characterized for their D4Z4 repeat size and haplotype and 
monitored for clinical features of FSHD.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Combined 18p- and FSHD phenotype in two independent families
Pedigrees of families Rf1731 (A) and Rf1877 (C). Individuals with a phenotypic 
combination of 18p- syndrome and FSHD are marked with filled symbols. Below each 
individual, the size of 18p deletion or duplication is shown, followed by the delta1 values 
reflecting DNA methylation levels at D4Z4 and the number of D4Z4 units on both 
chromosomes 4 as well as chromosomal background (A: 4qA FSHD permissive; B: 4qB 
non-permissive) are depicted. Images of Rf1731.102 and Rf1731.201 (B) and Rf1877.201 
(D) highlight facial characteristics compatible with 18p- syndrome, including ocular ptosis, 
strabismus, low-set ears. Right images show the presence of bilateral winging scapula which 
are characteristic of FSHD and is more pronounced on Rf1731.102 and Rf1877.201.
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Figure 2. Primary myoblasts originating from 18p- individuals presenting with a combined 18p-
and FSHD phenotype express DUX4
(A) Relative expression of SMCHD1 normalized to GUSB in control and 18p- myoblasts 
and myotubes. Values of 18p- 3 were set to 1. (B) Western blot analysis of SMCHD1 and 
HSP90 in myotubes having one or two copies of SMCHD1. (C) Quantification of western 
blot signals by normalizing SMCHD1 signal intensities to HSP90 signal intensities. P value 
was calculated by unpaired t-test followed by Mann-Whitney test. * represents p<0.05 and 
** represents p<0.01. (D) Expression levels of DUX4 normalized to GUSB in 
undifferentiated and differentiated primary myoblast cultures originating from control, from 
3 patients with FSHD phenotype and a microdeletion on chromosome 18p without 
presenting any 18p- phenotype (open bars) and from 18p- 9 and18p- 10 (solid black bars). 
(E) DUX4 (green signal) immunofluorescence analysis in differentiated myotubes with 
myosin (red signal) as differentiation marker in primary myotubes originating from 18p- 9, 
18p- 10 and FSHD1 3. High content screening was performed using a Nikon confocal 
microscope at 20× magnification and 2 representative images are shown for every cell 
culture.
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Hemizygosity of SMCHD1 is associated with reduced SMCHD1 transcript and protein 
levels in different tissues. SMCHD1 transcript levels determined by qRT-PCR and 
normalized to GUSB in primary fibroblasts (A) and LCLs (B). (C) SMCHD1 protein levels 
determined by western blot analysis in primary fibroblasts. (D) Intensity of SMCHD1 signal 
shown on panel C was normalized to Tubulin and statistical analysis of normalized values 
are shown. Scatter plots show mean and standard error of the mean. Statistical analysis was 
done by unpaired t-test followed Mann-Whitney test. * represents p<0.05 (D), ** represents 
p<0.01 (A) and ****represents p<0.0001 (B).
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Figure 4. The D4Z4 chromatin landscape is similar in FSHD2 and 18p- syndrome fibroblasts
(A) DNA methylation at D4Z4 in control and 18p- fibroblasts (n=6 control and n=8 18p-) is 
shown as percentage methylation at the FseI site. (B) SMCHD1 levels at D4Z4 measured by 
ChIP-qPCR in control and 18p- primary fibroblasts. SMCHD1 enrichment values are shown 
as normalized to input and enrichment values of control 1 sample were set to 1. H3K27me3 
(C) and H3K4me2 (D) levels at D4Z4 in the same samples shown in panel B. Histone 
modification levels are normalized to H3 and enrichment values of control 1 were set to 1. 
Statistical analysis was done by unpaired t-test followed Mann-Whitney test. * represents 
P<0.05 (B, C, D), ** represents P<0.01 (A).
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18p- fibroblasts express DUX4 after myogenic transdifferentiation. (A and B) Relative 
expression of MYH3 and DUX4 in MyoD (M) or GFP (G) transduced control (C) and 18p- 
primary fibroblasts (18p-). Expression values were normalized to GUSB and value of 18p-2 
was set to one. Bar diagrams show the mean and SD of 2 independent experiments. (C) 
Representative images of DUX4 protein detection by immunofluorescence staining at 20× 
magnification. Cells were stained with DAPI (nuclei; blue), DUX4 (green), and myogenic 
differentiation marker MYH1E (red) High content screening was performed by 
CellomicsArrayscan@VTI HCS instrument at 20× magnification and representative images 
are shown.
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DUX4 and DUX4 target gene expression in control, 18p- and FSHD1 LCLs. Relative 
expression of DUX4 (A) and DUX4 targets TRIM43 (B), ZSCAN4 (C), and MBD3L2 (D) 
in a cohort of control, FSHD1 and 18p- LCLs. Scatter plots show expression levels 
normalized to GUSB and relative expression level of FSHD1–2 was set to 1. Statistical 
analysis was done by one way ANOVA followed by Kruskal-Wallis test. * represents p<0.05 
(A, B), *** represents p<0.01 (C, D) and **** represents p<0.0001 (A, B).
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